StkExc/330 & 331 17<sup>th</sup> May, 2021

#### **BSELISTING**

#### **NEAPS**

The Secretary	The Manager, Listing Department		
BSE Limited,	National Stock Exchange of India Limited		
Phiroze Jeejeebhoy Towers,	'Exchange Plaza', C-1, Block G,		
Dalal Street,	Bandra Kurla Complex,		
Mumbai 400 001.	Bandra (East),		
	Mumbai 400 051		

Dear Sir,

## <u>Sub: Newspaper Advertisement - Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015</u>

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the Financials published in newspapers of MINT and Aapla Mahanagar. The above information will also be available on the website of the Company: www.skf.com/in .

Thanking you,

Yours faithfully, SKF India Limited

RANJAN

CORRESPONDENT SUPPLIANT SUPP

Ranjan Kumar Company Secretary

Encl: a/a

# Sputnik V jab on sale in India for ₹995 per dose

Dr Reddy's hopes to reduce price when local production begins from July

leroy.d@livemint.com

**NEW DELHI** 

rReddy's Laboratories Ltd will sell Sputnik V vaccine at ₹995 per dose for shots imported from Russia and has also begun the soft launch of the covid-19 vaccine in India using the 150,000 shots it had procured earlier this month.

"The imported doses of the vaccine are presently priced at an MRP (maximum retail price) of ₹948 + 5% GST per dose, with the possibility of a lower price point when local supply begins. The company is working closely with its six manufacturing partners in India to fulfil regulatory requirements to ensure smooth and timely supply," the company said in a statement on Friday.

The current price point is, however, higher than the "less than \$10 (₹732) per dose" indicated by the vaccine's global commercializing partner, Russian Direct Investment Fund (RDIF), in November. For the Centre and states, the vaccine is also priced much higher than Serum Institute of India's Covishield (₹300 per dose) and Bharat Biotech International's Covaxin (₹150 for Centre and ₹400 for states).

At a press conference earlier in the day,

**THE** current price

point is higher than the "less than \$10

indicated by RDIF

M.V. Ramana, Dr Reddy's chief executive officer for branded markets (India and emerging markets), said the company is looking to offer the vaccine at lower prices when local production starts from July, but for now, the pricing includes the cost of procure-

ment and transportation from Russia and for internal logistics in India.

He also said that limited doses are expected to be imported from Russia.

"We have a line of sight of 36 million doses for the next couple of months. We obviously are asking RDIF to allocate us more...While we have a confirmation for 36 (million), we are expecting we would get



Sputnik V involves giving two doses three weeks apart, with each dose made of different adenovirus vectors—Ad26 and Ad5 human adenoviruses

FOR now, the firm will

only supply to some hospitals where the

govt placed no orders

more than 36 (million)," Ramana said.

A second shipment of Sputnik V expected this week is intended for the second dose of the vaccine, he said, adding that Dr Reddy's is awaiting clarity on whether the consignment will comprise the entire 150,000 doses or a part of it.

Sputnik V involves giving two doses three weeks apart, with each dose made of

**EXPANDING VAX SUPPLY** 

**THE** drugmaker has a

line of sight of 36 million doses for the

months: India CEO

different adenovirus vectors-Ad26 and

For now, the company does not have

orders from the Union government and

states and will only supply to some hospi-

tals where the vaccine can be stored, Ram-

ana said. The Hyderabad-based drugmaker

will work closely with stakeholders in the

government and private sector in India to

Ad5 human adenoviruses.

ensure the widest possible reach of the Sputnik V vaccine.

"With the rising cases in India, vaccination is our most effective tool. Contributing to the vaccination drive in India is our biggest priority to help Indians be healthy and safe," G.V. Prasad, co-chairman and MD, Dr

Reddy's, said in the statement. Dr Reddy's signed a pact with RDIF to

market 250 million doses of the vaccine. The two-dose jab was developed by Moscow's Gamaleya Research Institute of Epidemiology and Microbiology, with RDIF responsible for commercializing the vaccine globally via manufacturing and distribution pacts.

Out of the total 250 million, Dr Reddy's will be importing about 15-20% in the next two months before local production kicks in, Ramana said. In India, RDIF has manufacturing pacts with six companies-Hetero Biopharma, Gland Pharma, Stelis Biopharma, Virchow Biotech, Panacea Biotec and Shilpa Medicare—to collectively produce over 850 million doses per year.

## BRICS hold talks on social security pacts

Prashant K. Nanda prashant.n@livemint.com NEW DELHI

labour conference among the five BRICS nations, Brazil, Russia, India, China, and South Africa. has taken New Delhi closer to signing social security agreements with the other member countries, the Union government said.

A social security agreement provides the benefits of detachment, totalization and portability. Detachment exempts international workers from making contribution in the host country and totalization allows the service rendered abroad to be counted for benefits in the home country, while portability allows benefits to be availed in either



India has been holding talks on the agreements with Brazil, Russia, China and South Africa since 2016.

"We had a detailed and fulfilling discussion on a social security agreement and the benefits it will have on the employees and employers. We have moved closer to agreements. Partner countries are willing to take negotiations

forward," labour and employment secretary Apurva Chandra said.

"We shall have a few more negotiations, perhaps at the individual country level, before proceeding further," said Chandra, who chaired a meeting with representatives of the BRICS nations and officials of the International Labour Organization (ILO).

Such agreements will help reduce dual social security deductions, allow pension portability, and lead to a reduction of employee cost for companies working in each other's country.

The Union cabinet had approved a plan in December 2019 to sign a bilateral social security agreement with Brazil. India has social security agreements with at least 19

countries, including Germany, Japan, and Australia and the Union labour ministry has been talking to its BRICS counterparts since 2016.

"With trade and investments growing among BRICS countries, there is an increasing flow of citizens who work for their companies in other nations... The companies often make dual contributions in the absence of detachments provisions that affect the competitiveness and increases employee cost," said another government official who did not want to be named.

The labour code on social security that has merged the multiple laws will make it easier to implement such agreements provided the other country is also keen to do so, the official said.

#### **Bharti Hexacom Limited**

Registered Office: Bharti Crescent, 1, Nelson Mandela Road, Vasant Kunj, Phase II, New Delhi – 110 070, India CIN: U74899DL1995PLC067527, T: +91-11-4666 6100, F:+91-11-4166 6137. Email id: bhartihexacom@bharti.in, Website: www.bhartihexacom.in

Audited Financial Results for the year ended March 31, 2021

(Rs. Millions; except per share data)

		Year ended			
S.No.	Particulars	March 31, 2021	March 31, 2020		
		Audited	Audited		
1	Total income from operations	46,023	38,741		
2	Loss before exceptional items and tax	(6,474)	(12,475)		
3	Loss before tax (after exceptional item)	(9,891)	(34,348)		
4	Loss for the year (after tax and exceptional item)	(10,339)	(27,165)		
5	Total comprehensive loss for the year	(10,340)	(27,167)		
6	Paid-up equity share capital (Face value : Rs. 10/- each)	2,500	2,500		
7	Other equity	17,360	27,700		
8	Net worth	18,987	29,327		
9	Outstanding debt	59,752	51,909		
10	Debt Equity Ratio	2.99	1.62		
11	Loss per share (Face value : Rs. 10/- each)				
	a) Basic	(41.36)	(108.66)		
	b) Diluted	(41.36)	(108.66)		
12	Debt Service Coverage Ratio - [no. of times]	0.86	` 0.64		
13	Interest Service Coverage Ratio - [no. of times]	2.57	1.34		

The above are extract of the detailed format of Audited Financial Results for the year ended March 31, 2021 filed with the Stock Exchanges under Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended from time to time). The full format of the annual financial results are available on the stock exchange websites (www.nseindia.com)

For the items referred in sub-clauses (a), (b), (d) and (e) of the Regulation 52 (4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the pertinent disclosures have been made to the National Stock Exchange of India and can be accessed on the URL (www.nseindia.com).

For Bharti Hexacom Limited

Gurugram May 14,2021

Nidhi Lauria Chief Executive Officer

Badal Bagri DIN:00367278



### Did you know?

## SKF has been a part of NASA's Perseverance Mars Rover

SKF has officially reached the Red Planet!

#### **SKF India Limited**

CIN: L29130MH1961PLC011980

Regd. Office: Mahatma Gandhi Memorial Building, Netaji Subhash Road, Charni Road, Mumbai: 400 002 Tel. No.: 91-22-22857777 | Fax: 91-22-2281 9074 | E-mail: investors@skf.com | Website: www.skf.com/in

FY20-21: Quarter - January to March 2021 and Full Year - April 2020 to March 2021









PBT for the year 2.5%



#### UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND ANNUAL AUDITED RESULT FOR THE YEAR ENDED MARCH 31, 2021

Particulars	Quarter Ended March 31, 2021 (Unaudited)	Quarter Ended December 31, 2020 (Unaudited)	Quarter Ended March 31, 2020** (Unaudited)	Year Ended March 31, 2021 (Audited)	Year Ended March 31, 2020** (Audited)
Revenue from Operations	8,475.3	8,187.2	6,102.1	26,707.3	28,415.8
Net Profit / (Loss) for the Period (Before Tax, Exceptional and/or Extraordinary items) #	1,387.0	1,736.5	918.3	3,962.9	3,867.7
Net Profit / (Loss) for the Period Before Tax (After Exceptional and/or Extraordinary items) #	1,387.0	1,736.5	918.3	3,962.9	3,867.7
Share of Profit/(Loss) of Associate	(0.4)	(0.0)	0.0	(0.4)	0.0
Net Profit / (Loss) for the Period After Tax (After Exceptional and/or Extraordinary items) #	1,048.3	1,281.1	753.4	2,976.9	2,889.9
Total Comprehensive Income for the Period [Comprehensive Profit / (Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax)]	1,073.3	1,291.3	680.7	3,012.1	2,798.3
Equity Share Capital	494.4	494.4	494.4	494.4	494.4
Reserves (Excluding Revaluation Reserve as Shown in the Audited Balance Sheet of Previous Year)				15,143.3	18,558.1
Earnings Per Share (of Rs.10/- each) (for Continuing and Discontinued Operations)					
1. Basic: (Not to be Annualised)	21.2	25.9	15.2	60.2	58.5
2. Diluted: (Not to be Annualised)	21.2	25.9	15.2	60.2	58.5

The consolidated financial are presented effective from quarter ending December 31, 2020.

These columns represents the unaudited Standalone Financial results for the quarter and annual audited results for the year ended # No exceptional and/or extra ordinary items in the above results

KEY NUMBERS OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND ANNUAL AUDITED RESULT FOR THE YEAR ENDED MARCH 31, 2021

					Rs in Millior
Particulars	Quarter Ended March 31, 2021 (Unaudited)	Quarter Ended December 31, 2020 (Unaudited)	Quarter Ended March 31, 2020 (Unaudited)	Year Ended March 31, 2021 (Audited)	Year Ended March 31, 2020 (Audited)
Revenue from Operations	8,475.3	8,187.2	6,102.1	26,707.3	28,415.8
Net Profit / (Loss) for the Period Before tax	1,387.0	1,736.5	918.3	3,962.9	3,867.7
Net Profit / (Loss) for the Period After Tax	1,048.7	1,281.1	753.4	2,977.3	2,889.9
Total Comprehensive Income for the Period [Comprehensive Profit / (Loss) for the Period (After Tax) and Other Comprehensive Income (After Tax)]	1,073.7	1,291.3	680.7	3,012.5	2,798.3

The above result were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on May 14, 2021.

The above is an extract of the detailed format of Quarterly / Annual Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly / Annual Financial Results are available on the Stock Exchange websites www.bseindia.com, www.nseindia.com and on the Company's website www.skf.com/in

c) During the year ended March 31, 2021, the Company has subscribed to 26.74% equity shares in Sunstrength Renewables Private Limited (SRPL), a company incorporated pursuant to the requirements of the Electricity Act, 2002 and the applicable rules for commissioning a captive generating plant for generation and supply of electricity to SKF and is in the final stage of commissioning. Since SRPL is considered as an 'associate' under Ind AS 28, Investments in Associates and Joint Ventures, these consolidated financial statements have been prepared for the year ended March 31, 2021. Comparative figures for the previous year are not applicable.

d) During the quarter ended December 31, 2020, in line with the transfer pricing mechanism followed consistently and reviewed periodically, there has been a reduction in purchase prices of the traded goods procured from SKF Group companies. This resulted in a significant improvement in the gross margins for the

The Board recommended a dividend of Rs. 14.50 per share on Equity Share of Rs. 10 each.
The figures for the quarter ended March 31 are the balancing figures between audited figures in respect of the full year ended March 31 and the published year to date figures upto the third quarter ended December 31 of the relevant financial year.

SKE India Limited

Date: May 14, 2021

Manish Bhatnagar Managing Director



केंद्राच्या फेरविचार याचिकेत राज्याने सहभागी व्हावे



फक्त कॉविन ३.० या ॲपवर लसीकरणाची नोंदणी करा









SKF has been a part of NASA's Perseverance Mars Rover

The second secon